about
Pharmacological treatment options for mast cell activation diseaseKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthSuberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report.Mastocytosis.Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Diagnosis and treatment of mast cell disorders: practical recommendations.Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Systemic mastocytosis: bone marrow pathology, classification, and current therapies.International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Mast cells and mastocytosis.Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat.Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816VKIT and mastocytosis.Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.Diagnosis, progression patterns and prognostication in mastocytosis.Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Severe chronic diarrhea and maculopapular rash: a case reportMastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's DiseaseSystemic mastocytosis with associated acute myelogenous leukemia.The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.Versatile synthesis and biological evaluation of novel 3'-fluorinated purine nucleosides
P2860
Q26748784-356802E4-0734-4CD4-AD20-FEE153C84D0DQ26830207-FE129CE1-2533-4AF2-8B0C-45009292427CQ28828739-A74FA877-92A7-4A38-AC13-CCA9316304A8Q30303153-066E7BFE-AB2D-454F-B607-0E4A672B4700Q33159586-3DAA2088-AB1A-4AAC-8F81-B7148728B609Q33163541-773381C4-3C2B-4515-B7FB-BCEB6E3B8419Q33406035-DD598AD2-A06E-4AB2-AB09-1A3BCA1020A7Q34552564-CDAAB77C-0F43-4444-9371-E4BF7FCAF4D9Q34664111-FB78A4C2-BE17-4D46-BEEE-6412D692A127Q35021196-E2E1E723-F48B-4EEB-ABDA-E5A0CF190AF0Q35848377-328ACA88-5D21-4023-9491-AD5356BB412AQ35854970-72C9A11A-433C-4711-B4CF-3F49CBBBCE72Q36182749-AB3E9148-89FA-4F97-9A01-B8B0A4D911F1Q36730397-95F158A1-05A7-4BD4-AB59-57D3669C8300Q36835143-124B7B1B-3C0E-4622-8050-7A8830A564A1Q37048439-B38BA6ED-0021-447D-B5A8-28463DA39C4AQ37144902-F738AD72-D2E8-40C9-BEB8-B6950859A579Q37195681-1AAFCF5B-6222-4460-9E15-7FF88EFA2594Q37247964-90471A10-E14E-497B-B03D-FE9377E25427Q37810130-E8245129-6A2D-4545-8336-D3279EB4537BQ37892475-C6F7DC46-D35B-4958-9EB4-722E5A78FC5EQ37992835-8A580A02-2FE8-42C4-BA02-E651419B05AFQ38025156-19CE0189-0AA2-419B-8D60-46B0CBF9B0BEQ38045311-89C1753A-839D-45CE-8962-FCB2109561F8Q38110527-BAB376C5-B57E-4FC2-A620-CF30886AB9B8Q38358282-52F97248-AAEA-4B93-A95C-E480EA1F92D5Q38370943-9FE09830-D050-4ECE-B613-B0215026028FQ38661465-12CF65BE-08F3-4967-83CA-BACEC2AE29A7Q38773595-C8B23EFE-D394-4DBA-B66C-9C329BF26D3BQ38777126-8A57D7A0-07A6-45C8-95DB-77E350FEE6BBQ39267824-D2CFBFEB-AE24-417F-BBAA-5A9F8F1AAFF7Q39348704-25A88799-4BC4-4659-B556-736590B5E853Q39689493-44255500-771B-44E3-9EB4-90E0E8D713F4Q39779573-BECAEECF-3683-40F2-9BF6-F58A52130B8FQ40298579-D10ED97B-52F0-4E39-A45C-9FD3A50B524BQ41225286-ACC458E8-8284-431F-8270-4F80F3F7D1AEQ41852159-886145DD-7B19-4384-864A-BA4CC1FFDC12Q42148789-C908E33A-74A0-4C63-B282-9F95CFAD9310Q42234623-0CDCBC38-AE84-42BF-B165-D98BB71D5BCDQ42658238-63648EF2-1491-47E0-A97B-DB62E61A0EFA
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cladribine therapy for systemic mastocytosis.
@en
Cladribine therapy for systemic mastocytosis.
@nl
type
label
Cladribine therapy for systemic mastocytosis.
@en
Cladribine therapy for systemic mastocytosis.
@nl
prefLabel
Cladribine therapy for systemic mastocytosis.
@en
Cladribine therapy for systemic mastocytosis.
@nl
P2093
P1433
P1476
Cladribine therapy for systemic mastocytosis
@en
P2093
Gregor Verhoef
J Marja Oldhoff
Jan W Van 't Wout
Jasper J Van Doormaal
O Aart van Dobbenburgh
Rob Fijnheer
Suzanne G Pasmans
Wim B J Gerrits
P304
P356
10.1182/BLOOD-2003-05-1699
P407
P577
2003-08-21T00:00:00Z